104 related articles for article (PubMed ID: 1309044)
1. Possibilities of intervention in intrinsic and extrinsic lysis programs.
Lowe GD
Ann N Y Acad Sci; 1992 Dec; 667():272-7. PubMed ID: 1309044
[No Abstract] [Full Text] [Related]
2. [Plasminogen activator inhibitors from neoplastic tissues].
Mirowski M; Wierzbicki R
Postepy Hig Med Dosw; 1991; 45(1-2):119-27. PubMed ID: 1923993
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic changes and the influence of the early perfusate in orthotopic liver transplantation with intraoperative aprotinin treatment.
Himmelreich G; Kierzek B; Neuhaus P; Slamer KJ; Riess H
Transplant Proc; 1991 Jun; 23(3):1936-7. PubMed ID: 1712137
[No Abstract] [Full Text] [Related]
4. Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures.
Dosne AM; Beaupain R; Samama M
Semin Thromb Hemost; 1991 Jul; 17(3):240-5. PubMed ID: 1796296
[No Abstract] [Full Text] [Related]
5. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
Krishnamurti C; Alving BM
Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
[No Abstract] [Full Text] [Related]
6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
7. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
8. Placenta and myometrium--the two main sources of fibrinolytic components during pregnancy.
Uszyński M; Maciejewski K; Uszyński W; Kuczyński J
Gynecol Obstet Invest; 2001; 52(3):189-93. PubMed ID: 11598362
[TBL] [Abstract][Full Text] [Related]
9. Advances in clinical fibrinolysis.
Hessel LW; Kluft C
Clin Haematol; 1986 May; 15(2):443-63. PubMed ID: 2942332
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease.
Meyers DG; Haire WD; Rasmussen JK; Boyd EJ
Angiology; 1991 Jul; 42(7):561-7. PubMed ID: 1907440
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic effect after sequential double-bolus administration of tissue plasminogen activator and urokinase-fibrinogen conjugate into dogs with venous thrombosis.
Maksimenko AV; Tischenko EG; Golubykh VL
Ann N Y Acad Sci; 1998 Dec; 864():409-17. PubMed ID: 9928118
[No Abstract] [Full Text] [Related]
12. [Fibrinolytic tests and the related factors].
Matsuda T
Nihon Naika Gakkai Zasshi; 1991 Jun; 80(6):834-8. PubMed ID: 1919196
[No Abstract] [Full Text] [Related]
13. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
15. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
17. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
18. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
19. Tissue plasminogen activator: from molecular biology to myocardial infarction.
Chien KR; Meidell R; Gerard R
Am J Med Sci; 1987 Mar; 293(3):201-7. PubMed ID: 3105313
[TBL] [Abstract][Full Text] [Related]
20. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]